-
1دورية أكاديمية
المؤلفون: Gregson, J.M., Freitag, D.F., Surendran, P., Stitziel, N.O., Chowdhury, R., Burgess, S., Kaptoge, S., Gao, P., Staley, J.R., Willeit, P., Nielsen, S.F., Caslake, M., Trompet, S., Polfus, L.M., Kuulasmaa, K., Kontto, J., Perola, M., Blankenberg, S., Veronesi, G., Gianfagna, F., Männistö, S., Kimura, A., Lin, H., Reilly, D.F., Gorski, M., Mijatovic, V., Munroe, P.B., Ehret, G.B., Thompson, A., Uria-Nickelsen, M., Malarstig, A., Dehghan, A., Vogt, T.F., Sasaoka, T., Takeuchi, F., Kato, N., Yamada, Y., Kee, F., Müller-Nurasyid, M., Ferrières, J., Arveiler, D., Amouyel, P., Salomaa, V., Boerwinkle, E., Thompson, S.G., Ford, I., Wouter Jukema, J., Sattar, N., Packard, C.J., Shafi Majumder, A.A., Alam, D.S., Deloukas, P., Schunkert, H., Samani, N.J., Kathiresan, S., Nordestgaard, B.G., Saleheen, D., Howson, J.M., Di Angelantonio, E., Butterworth, A.S., Danesh, J.
المساهمون: CKDGen consortium, International Consortium for Blood Pressure, CHARGE inflammation working group, MICAD Exome consortium, EPIC-CVD consortium and the CHD Exome+ consortium
المصدر: European journal of preventive cardiology, vol. 24, no. 5, pp. 492-504
مصطلحات موضوعية: 1-Alkyl-2-acetylglycerophosphocholine Esterase/drug effects, 1-Alkyl-2-acetylglycerophosphocholine Esterase/genetics, Adult, Aged, Alleles, Benzaldehydes/therapeutic use, Case-Control Studies, Coronary Disease/diagnosis, Coronary Disease/drug therapy, Coronary Disease/genetics, Female, Gene Expression Regulation, Genotype, Humans, Male, Middle Aged, Molecular Targeted Therapy, Oximes/therapeutic use, Phospholipase A2 Inhibitors/therapeutic use, Polymorphism, Single Nucleotide, Randomized Controlled Trials as Topic, Reference Values, Reproducibility of Results, Risk Assessment, Treatment Outcome, Human genetics, coronary heart disease, darapladib, lipoprotein-associated phospholipase A2
وصف الملف: application/pdf
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/27940953; info:eu-repo/semantics/altIdentifier/eissn/2047-4881; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_4856BCF7E2789; https://serval.unil.ch/notice/serval:BIB_4856BCF7E278Test; urn:issn:2047-4873; https://serval.unil.ch/resource/serval:BIB_4856BCF7E278.P001/REF.pdfTest; http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_4856BCF7E2789Test
الإتاحة: https://doi.org/10.1177/2047487316682186Test
https://serval.unil.ch/notice/serval:BIB_4856BCF7E278Test
https://serval.unil.ch/resource/serval:BIB_4856BCF7E278.P001/REF.pdfTest
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_4856BCF7E2789Test -
2
المؤلفون: Fruchart, J.C., Santos, R.D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P.J., Ceska, R., Corsini, A., Després, J.P., Duriez, P., Eckel, R.H., Ezhov, M.V., Farnier, M., Ginsberg, H.N., Hermans, M.P., Ishibashi, S., Karpe, F., Kodama, T., Koenig, W., Krempf, M., Lim, S., Lorenzatti, A.J., McPherson, R., Nuñez-Cortes, J.M., Nordestgaard, B.G., Ogawa, H., Packard, C.J., Plutzky, J., Ponte-Negretti, C.I., Pradhan, A., Ray, K.K., Reiner, Ž., Ridker, P.M., Ruscica, M., Sadikot, S., Shimano, H., Sritara, P., Stock, J.K., Su, T.C., Susekov, A.V., Tartar, A., Taskinen, M.R., Tenenbaum, A., Tokgözoğlu, L.S., Tomlinson, B., Tybjærg-Hansen, A., Valensi, P., Vrablík, M., Wahli, W., Watts, G.F., Yamashita, S., Yokote, K., Zambon, A., Libby, P.
المصدر: Cardiovascular diabetology, vol. 18, no. 1, pp. 71
مصطلحات موضوعية: Animals, Benzoxazoles/adverse effects, Benzoxazoles/therapeutic use, Biomarkers/blood, Butyrates/adverse effects, Butyrates/therapeutic use, Cardiovascular Diseases/blood, Cardiovascular Diseases/diagnosis, Cardiovascular Diseases/prevention & control, Consensus, Dyslipidemias/blood, Dyslipidemias/diagnosis, Dyslipidemias/drug therapy, Humans, Hypolipidemic Agents/adverse effects, Hypolipidemic Agents/therapeutic use, Lipids/blood, Molecular Targeted Therapy, PPAR alpha/agonists, PPAR alpha/metabolism, Patient Safety, Risk Assessment, Risk Factors, Signal Transduction, Treatment Outcome, Atherogenic dyslipidemia, Diabetes, Inflammation, PROMINENT, Pemafibrate (K-877), Remnant cholesterol, Residual cardiovascular risk, SPPARMalpha, Selective peroxisome proliferator-activated receptor alpha modulator, Triglycerides, Visceral obesity
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______1900::1e42e4b07a96300e14b1450540aec81bTest
https://serval.unil.ch/resource/serval:BIB_A62033B5071E.P001/REF.pdfTest